Trending...
- Eliza Nevius Reimagines a Classic with a Dark, Witty Twist in The Key to Wonderland
- Ironside HR Named Fastest-Growing Staffing Firm for Second Year
- Entyre Solutions Launches to Support Senior Living Operators
BOSTON, Oct. 10, 2024 ~ Chicago, IL - Sensorium Therapeutics, a biotechnology company focused on developing innovative medicines for central nervous system (CNS) diseases, presented positive preclinical data on their lead programs at Neuroscience 2024. The company also shared details on the capabilities of its Biodynamic Discovery Platform™ at the conference held this week in Chicago.
The preclinical data presented at the conference highlighted the potential of Sensorium's unique drug discovery strategy. This approach combines medicinal chemistry, advanced neuronal screening models, and machine learning to develop novel first-in-class CNS medicines inspired by natural compounds and supported by proven human efficacy and safety data.
"We are excited to share these promising results that validate our de-risked drug development approach," said Alexandra Glucksmann, PhD, CEO of Sensorium. "These findings further demonstrate the potential of our platform to deliver breakthrough CNS medicines as we prepare to enter clinical trials next year."
The company's lead programs, SENS-01 and SENS-03, were the focus of the presentation. SENS-01 is a novel highly selective fast-acting anxiolytic for the treatment of anxiety disorders. It is a synthetic derivative of a natural compound with proven human validation as a fast onset anxiolytic. The molecule has shown excellent CNS drug-like properties with a clean safety profile and in vivo efficacy in multiple models. Currently completing IND-enabling studies, SENS-01 is expected to enter clinical trials in early 2025.
More on illi News
SENS-03 is another promising program being developed by Sensorium. It is a novel chemical entity with a differentiated mechanism of action to address focal onset seizures in drug-resistant epilepsy patients. This program also has potential to address comorbid anxiety, which affects 80% of patients with drug-resistant epilepsy. Preclinical data has shown efficacy in multiple validated seizure models as well as preclinical anxiety models.
Sensorium's Biodynamic Discovery Platform™ was also highlighted at the conference. This platform utilizes an advanced and comprehensive integrated ethnopharmacological knowledge graph to discover molecules with proven human efficacy. Novel cellular models, including human iPSC-derived and rodent primary neural systems, are used to define differentiation and novel pharmacology for compounds. This data provides valuable insights for advancing novel drug candidates.
"We are proud of the progress we have made with our Biodynamic Discovery Platform™," said Jeffrey Brown, PhD, Chief Scientific Officer at Sensorium. "It has allowed us to identify and advance a novel therapeutic for the treatment of epilepsy with comorbid anxiety, as well as other potential treatments for CNS diseases."
More on illi News
The company's poster presentations at Neuroscience 2024 included details on SNTX-AXN, a novel fast-acting anxiolytic discovered and developed from Sensorium's AI-driven product engine. The presentation highlighted the molecule's differentiated pharmacology from standard of care and its proven efficacy in both in vitro and in vivo studies.
Another poster presentation focused on Sensorium's SENS-AI Platform, which identified a natural compound with human validation for both anxiolytic and anti-epileptic properties. Chemical optimization of this compound led to novel synthetic derivatives that maintain its efficacy while improving its CNS-drug like properties.
In addition, Sensorium presented data on their Discovery Platform for Phenotypic Characterization of Natural Products in IPSC-Derived and Primary Neuronal Models. This platform has been instrumental in advancing novel drug classifiers and providing mechanistic insight for compounds currently being developed by the company.
Overall, the positive preclinical data presented by Sensorium at Neuroscience 2024 highlights the potential of their unique drug discovery approach to deliver much-needed treatments for CNS diseases. With plans to enter clinical trials next year, the company is well-positioned to make significant contributions to this field.
The preclinical data presented at the conference highlighted the potential of Sensorium's unique drug discovery strategy. This approach combines medicinal chemistry, advanced neuronal screening models, and machine learning to develop novel first-in-class CNS medicines inspired by natural compounds and supported by proven human efficacy and safety data.
"We are excited to share these promising results that validate our de-risked drug development approach," said Alexandra Glucksmann, PhD, CEO of Sensorium. "These findings further demonstrate the potential of our platform to deliver breakthrough CNS medicines as we prepare to enter clinical trials next year."
The company's lead programs, SENS-01 and SENS-03, were the focus of the presentation. SENS-01 is a novel highly selective fast-acting anxiolytic for the treatment of anxiety disorders. It is a synthetic derivative of a natural compound with proven human validation as a fast onset anxiolytic. The molecule has shown excellent CNS drug-like properties with a clean safety profile and in vivo efficacy in multiple models. Currently completing IND-enabling studies, SENS-01 is expected to enter clinical trials in early 2025.
More on illi News
- Naperville: Structure Fire in the 200 Block of South Columbia St.
- Exelon Leader Tamla Olivier Named 2025 Technologist of the Year by Waves of Change STEM Conference
- MolecuLight "Lights the Way to Equitable Wound Care" at National Medical Association Conference
- Be Part of the World's Largest Art Biennale | Moons, Castles, Trees | Copenhagen Chronotopes
- SeedList Launching Institutional Crypto Crowdfunding Project to Empower Retail Investors and Disrupt the VC-Dominated Crypto Fundraising Landscape
SENS-03 is another promising program being developed by Sensorium. It is a novel chemical entity with a differentiated mechanism of action to address focal onset seizures in drug-resistant epilepsy patients. This program also has potential to address comorbid anxiety, which affects 80% of patients with drug-resistant epilepsy. Preclinical data has shown efficacy in multiple validated seizure models as well as preclinical anxiety models.
Sensorium's Biodynamic Discovery Platform™ was also highlighted at the conference. This platform utilizes an advanced and comprehensive integrated ethnopharmacological knowledge graph to discover molecules with proven human efficacy. Novel cellular models, including human iPSC-derived and rodent primary neural systems, are used to define differentiation and novel pharmacology for compounds. This data provides valuable insights for advancing novel drug candidates.
"We are proud of the progress we have made with our Biodynamic Discovery Platform™," said Jeffrey Brown, PhD, Chief Scientific Officer at Sensorium. "It has allowed us to identify and advance a novel therapeutic for the treatment of epilepsy with comorbid anxiety, as well as other potential treatments for CNS diseases."
More on illi News
- California Family Launches Billboard to Reach "Pardon Czar" Alice Marie Johnson
- MAZ6R CLAN Celebrated Our Exciting One Year Anniversary on July 1, 2025!
- Rent Like A Champion Acquires CollegeWeekends
- Sumter Landing Dental Care Launches Summer Special on Full Mouth Reconstruction
- Seligson Law Launches New Website to Support Cannabis Businesses in California and New York
The company's poster presentations at Neuroscience 2024 included details on SNTX-AXN, a novel fast-acting anxiolytic discovered and developed from Sensorium's AI-driven product engine. The presentation highlighted the molecule's differentiated pharmacology from standard of care and its proven efficacy in both in vitro and in vivo studies.
Another poster presentation focused on Sensorium's SENS-AI Platform, which identified a natural compound with human validation for both anxiolytic and anti-epileptic properties. Chemical optimization of this compound led to novel synthetic derivatives that maintain its efficacy while improving its CNS-drug like properties.
In addition, Sensorium presented data on their Discovery Platform for Phenotypic Characterization of Natural Products in IPSC-Derived and Primary Neuronal Models. This platform has been instrumental in advancing novel drug classifiers and providing mechanistic insight for compounds currently being developed by the company.
Overall, the positive preclinical data presented by Sensorium at Neuroscience 2024 highlights the potential of their unique drug discovery approach to deliver much-needed treatments for CNS diseases. With plans to enter clinical trials next year, the company is well-positioned to make significant contributions to this field.
Filed Under: Business
0 Comments
Latest on illi News
- $14M Deal with Famed David Lloyd for Sports, Entertainment & Gaming, AI Powered Fan Engagement Company; New Stock CUSIP; Creating Shareholder Value
- Disposable Vape Ban Spurs Hayati Innovation
- Prolific Hollywood "Unknown Actor" Leads 11 Day SoCal, Hands-On, Performer Employment Securing Residency that Shows Others How to Get More Work
- Dr. Harmon Completes Prestigious Zygomatic Implant Residency in Brazil
- Agreement to Deliver Thin-Film Solar Technology to Space Solar Array Provider, NASA Collaborative Agreement for Orbital Applications in Power Beaming
- Iterators LLC Honored with IST82 State Award for Accessibility in Massachusetts
- Samyang Corporation Unveils 'AI-Based Standardized Sugar Reduction Solution' at US Food Technology Expo
- Josh & Heidi Share Upcoming "Spreading the Good BUZZ" Podcast Guests, Select Top Five Elopement Locations as Their Instagram Presence Grows Globally
- Opteamix Launches StackRewrite.AI to Transform Enterprise Legacy Modernization
- Chicago's Premier Family-Friendly Festival Returns for its 4th Year!
- eVertiSKY Launches UAM Colony 2030 App:
- "The Pornified Generation": Dr. Chris Samuels Exposes the Toxic Alliance Between Bro Culture and Pornography That's Rewiring a Generation
- Final Weeks To See Bunny Watercolor Painting
- The Modern Insurance Store Expands Medicare Help Services for Seniors in Cincinnati
- Ironside HR Named Fastest-Growing Staffing Firm for Second Year
- Inframark Continues to Build Its Community Management Capabilities and Multi-Disciplinary Presence in Arizona
- ICAST 2025: The Crystal-Clear Revolution Begins at Booth #3233
- Brindle Pet Supplies Now Carries Badlands Ranch Dog Food in Canada
- Katten Partners Adam Klein and Daniel Render Named "Sports Power Lawyers"
- $10 Million Allocated to Establish Crypto Treasury Focused on High Value Ethereum (ETH) & Bitcoin (BTC) as Long-Term Holdings for Cybersecurity Leader